Nereus Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nereus Pharmaceuticals, Inc.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
China’s healthcare sector was back to actively raising proceeds from the capital markets in March and April, which witnessed more than 20 IPOs in total, with a stream of other listings being planned.
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Array BioPharma, a company focused on discovering and developing targeted small-molecule drugs to treat cancer and inflammatory diseases has appointed Dr Howard Holden vice-president of regulatory affairs and quality assurance. Dr Holden served as senior vice-president of regulatory affairs and compliance at Nereus Pharmaceuticals from 2005-2012.